Back to top
more

AVEO Pharmaceuticals, Inc. (AVEO)

(Delayed Data from NSDQ)

$0.94 USD

0.94
1,186,754

+0.04 (4.01%)

Updated May 3, 2019 04:00 PM ET

After-Market: $0.91 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options

Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

    AVEO (AVEO) Up 25.3% Since Last Earnings Report: Can It Continue?

    AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss

      AVEO Pharmaceuticals' (AVEO) loss in the second quarter meets estimates while revenues miss the same.

        AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Lags Revenue Estimates

        AVEO (AVEO) delivered earnings and revenue surprises of -150.00% and -67.93%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

          AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?

          On AVEO Pharmaceuticals' (AVEO) second-quarter 2018 conference call, investors' focus will remain on the company's progress with its drug Fotivda for the first-line treatment of RCC.

            AVEO Pharmaceuticals (AVEO) Soars: Stock Adds 11.8% in Session

            AVEO Pharmaceuticals (AVEO) was a big mover last session, as the company saw its shares rise more than 11% on the day amid huge volumes.

              Do Options Traders Know Something About AVEO Pharmaceuticals (AVEO) Stock We Don't?

              Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

                Why Is AVEO Pharmaceuticals (AVEO) Down 1.6% Since Its Last Earnings Report?

                AVEO Pharmaceuticals (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected

                  AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the first quarter while revenues come almost in-line with estimates. Data from TIVO-3 study postponed. Shares down.

                    AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?

                    AVEO Pharmaceuticals' (AVEO) first drug, Fotivda for the first-line treatment of RCC is likely to have a favorable impact on first-quarter results.

                      Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock

                      Surging implied volatility makes AVEO Pharmaceuticals (AVEO) lucrative to the option traders.

                        AVEO Down 7.7% Since Earnings Report: Can It Rebound?

                        AVEO reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                          Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)

                          Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)

                            Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock

                            AVEO Pharmaceuticals (AVEO) needs investors to pay close attention to the stock based on moves in the options market lately.

                              AVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down

                              AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the fourth quarter with revenues missing estimates. The top line also declines year over year.

                                AVEO Pharmaceuticals (AVEO) Q4 Loss Wider, Revenues Miss

                                AVEO Pharma (AVEO) posted wider-than-expected loss in the fourth quarter of 2017. Revenues missed estimates and were also lower than year ago figure.

                                  AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?

                                  AVEO Pharmaceuticals (AVEO) launched its first drug, Fotivda, as first-line treatment for RCC in Europe in November. This is likely to have a favorable impact on fourth-quarter results.

                                    AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda

                                    AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).

                                      Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options

                                      Investors in AVEO Pharmaceuticals (AVEO) need to pay close attention to the stock based on moves in the options market lately.

                                        AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda

                                        AVEO Pharmaceuticals reported narrower-than-expected adjusted loss in the third quarter. Moreover, it received approval for its first drug, Fotivda, which was approved in EU for bladder cancer.

                                          Is AVEO Pharmaceuticals Poised for a Beat in Q3 Earnings?

                                          AVEO Pharmaceuticals received approval for its first drug, Fotivda, as first-line treatment for RCC in Europe during the quarter. This is likely to have a favorable impact on third-quarter results.

                                            AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected

                                            AVEO Pharmaceuticals (AVEO) reported narrower-than-expected adjusted loss in the second quarter. Its kidney cancer candidate, tivozanib is nearing approval in EU with positive CHMP recommendation.

                                              AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?

                                              AVEO Pharmaceuticals (AVEO) depends on collaboration revenues and milestone and other payments for its top line. The CHMP recommendation for tivozanib MAA received during the quarter was a positive.

                                                Company News for July 10, 2017

                                                Companies in the News are: BRK.A,SPA,AVEO,ABCO,UNH

                                                  AVEO Pharmaceuticals (AVEO) Worth a Look: Stock Up 14.8%

                                                  AVEO Pharmaceuticals, Inc. (AVEO) shares rose around 15% in the last trading session.